← Back to Search

Cannabinoid

Cannabis for Memory Effects

Phase 2
Recruiting
Led By Ryan McLaughlin, PhD
Research Sponsored by Washington State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this outcome will be continuously assessed from before drug/placebo administration to immediately before they leave the lab (approximately 5 hours).

Summary

This trial examines how cannabis affects memory. Eligible participants will take tests & wear a wristband. They'll inhale vapor with/without THC & complete tests. Researchers hypothesize that those inhaling cannabis will perform worse on memory tests than those inhaling placebo.

Who is the study for?
This trial is for individuals who have used cannabis at least once a week for over a year and are willing to abstain from using it on the day of testing. Participants will be screened for drug use, wear an Empatica E4 wristband, and provide saliva samples.
What is being tested?
The study tests how different amounts of THC in cannabis (20mg or 40mg) versus placebo affect memory functions. Participants will undergo various memory tests after inhaling vaporized cannabis or placebo provided by NIDA.
What are the potential side effects?
Potential side effects include impairment in different types of memory such as prospective, verbal, visuospatial, source, working memory, false memories and temporal order recall. Other effects may include changes in mood, anxiety levels and stress.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this outcome will be assessed during the testing session, within 90 min post-treatment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and this outcome will be assessed during the testing session, within 90 min post-treatment. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Bell Ring Prospective Memory Test
Memory
Delayed Visuospatial Memory
+15 more
Secondary study objectives
Anxiety Rating Change Score (Baseline to Mid-testing)
Anxiety Rating Change Score (Baseline to Post-testing)
Anxiety Rating Change Score (Baseline to Post-treatment)
+20 more
Other study objectives
Cannabis Consumption Patterns
Drug Screen
Electrodermal Activity
+4 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 40mg THCExperimental Treatment1 Intervention
Participants will inhale vapor from .34 grams of cannabis containing 11.86% THC (40mg THC total).
Group II: 20mg THCExperimental Treatment1 Intervention
Participants will inhale vapor from .17 grams of cannabis containing 11.86% THC (20mg THC total).
Group III: PlaceboPlacebo Group1 Intervention
Participants will inhale vapor from a placebo product.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cannabis
2014
Completed Phase 3
~780

Find a Location

Who is running the clinical trial?

Washington State UniversityLead Sponsor
108 Previous Clinical Trials
57,412 Total Patients Enrolled
Ryan McLaughlin, PhDPrincipal InvestigatorWashington State University
Carrie CuttlerPrincipal InvestigatorWashington State University
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top